MINYANVILLE ORIGINAL Dynavax Technologies (NASDAQ:DVAX) a company given up for dead just a few years ago is getting a boost Tuesday on hope that its vaccine for hepatitis B will be approved for sale. Documents released by Food and Drug Administration staff ahead of review of the drug this week didn’t raise any major concerns about the safety or effectiveness of the treatment. That was enough to send the shares up 19% to $4.97 in midday trading Tuesday. The stock is now up 75% in the past 12 months and has made quite a comeback since trading at $0.16 ...